| Name | Title | Contact Details |
|---|
QualCare, Inc., one of the region`s leading providers of health care coverage, provides the public and private marketplace with a higher-quality, lower-cost alternative to commercial insurance companies. QualCare`s network covers over 100 acute, specialty and rehabilitation hospitals, as well as over 31,000 physicians and other ancillary providers across New Jersey, New York and Pennsylvania. Founded in 1991 from a consortium of hospital systems, QualCare has experienced dramatic growth over the past two decades. Currently, 16 of New Jersey`s largest and most successful hospitals own and serve on QualCare`s Board of Directors. QualCare services over 900,000 members, with a clientele that spans health systems, unions, local governments, school boards, small to large businesses and some of New Jersey`s largest corporations. With rate increases that are consistently below industry standards and unparalleled service satisfaction, QualCare is well positioned to succeed in the changing healthcare industry.
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.
We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.
Hospice By The Bay is a non-profit, hospice and palliatve care and grief counseling provider offering compassionate care to patients, families.
Can-Med Healthcare is a Bedford, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.